KRAS Clinical Trials

Through the KRAS Excellence Initiative (KRAS-X) at NYU Langone’s Perlmutter Cancer Center, people with KRAS-driven cancers and their providers can learn about current and upcoming clinical trials.

We’ve organized the following list by mutation type. For study details, click on the links below.

KRAS G12C

Investigator: Elaine Shum, MD

Investigator: Rajwanth Veluswamy, MD

Investigator: Joshua K. Sabari, MD

Investigator: Salman R. Punekar, MD

Investigator: Rajwanth Veluswamy, MD

Investigator: Joshua K. Sabari, MD

Investigator: Joshua K. Sabari, MD

EAY191-E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial (Pending)

Investigator: Kristen Spencer, DO

KRAS G12D

A Study to Investigate Treatment with TCR-engineered T cells Recognizing KRAS Mutations Adult Subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors (Pending)

Investigator: Salman R. Punekar, MD

Investigator: Paul E. Oberstein, MD

Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients with Solid Tumors with KRASG12D Mutation (Pending)

Investigator: Kristen Spencer, DO

Investigator: Kristen Spencer, DO

Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors (Pending)

Investigator: Paul E. Oberstein, MD

Investigator: Paul E. Oberstein, MD

Incyte IN- A Randomized, Double Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (Pending)

Investigator: Manuel Hidalgo Medina, MD

KRAS G12V

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants with Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s) G12V (Pending)

Investigator: Rajwanth Veluswamy, MD

Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients with Advanced KRAS G12V-Mutant Solid Tumors (Pending)

Investigator: Salman R. Punekar, MD

Pan (Multi) RAS

Investigator: Salman R. Punekar, MD

Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer (Pending)

Investigator: Rajwanth Veluswamy, MD

Investigator: Kristen Spencer, DO

A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations (Pending)

Investigator: Salman R. Punekar, MD

RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator’s Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (Pending)

Investigator: Paul E. Oberstein, MD

Phase 3 Study of Daraxonrasib in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC) (Pending)

Investigator: Paul E. Oberstein, MD

RAS-BRAF

A study to investigate the safety and efficacy of NST-628 oral tablets in subjects with solid tumors (Pending)

Investigator: Janice Mehnert, MD

Phase 1, FIH, open-label, nonrandomized, multicenter study of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway (Pending)

Investigator: Rajwanth Veluswamy, MD